The Federation of State Medical Boards shared a letter they received from the U.S. Food and Drug Administration (FDA) with information related to compounded drug products containing cagrilintide, some of which claim to treat obesity and other conditions. The FDA has asked us to share this letter with our member boards to make licensees aware of the current regulatory status of compounded cagrilintide. The FDA shared a similar letter with FSMB in early April about a compounded drug called retatrutide. If you have questions about any issues related to drug compounding, the FDA encourages you to reach out to the Office of Compounding Quality and Compliance at compounding@fda.hhs.gov.

See the Alabama Board of Medical Examiners' Declaratory Ruling on physicians compounding drugs or drug products.